[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
864953-29-7
99%
Bottle,barrel,cargo,container,etc.
Yes
2026-11-14
Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals
-
Product Description
-
Seller Information
-
DescriptionKeywords
864953-29-7
[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
Quick DetailsProName:[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
CasNo:864953-29-7
Appearance:powder, or liquid
Application:Pharmaceuticals, intermediates, APIs, custom synthesis, chemicals
DeliveryTime:5-7 Days
PackAge:Bottle, barrel, cargo, container, etc.
Port:Shanghai
Purity:99
Storage:Stored in room temperature, ventilated place
Transportation:By air, ship, express, etc.
LimitNum:0
Grade:Industrial Grade
SuperiorityBest Seller, High Quality, Competitive Price, Fast Delivery, Quick Response
DetailsLEAPChem supplies high quality Pharmaceuticals, intermediates, APIs, custom synthesis, fine chemicals and other industrial chemicalsECHEMI Editorial ReferenceFostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the HIV-1 viral lifecycle. The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically orthogonal therapies) for the treatment of HIV-1 patients with resistant infections. Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant HIV-1 infection whom are failing their current therapy. Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments.Basic Info-
Product Name:
Fostemsavir
Other Name:BMS 663068;BMS663068;BMS-663068-03;Fostemsavir(BMS-663068);Fostemsavir;1-(4-Benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-ethanedione;[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate;BMS663068 Fostemsavir
CAS No.:864953-29-7
Molecular Formula:C25H26N7O8P
InChIKeys:SWMDAPWAQQTBOG-UHFFFAOYSA-N
Molecular Weight:583.49
Exact Mass:583.49
UNII:97IQ273H4L
DSSTox ID:DTXSID40235596
Color/Form:White to off-white
ATC Code:J05AX|J - Antiinfectives for systemic use
Categories:
Characteristics-
Density:
1.60±0.1 g/cm3(Predicted)
Boiling Point:904.1±75.0 °C(Predicted)
Water Solubility:>250mg/mL
PKA:1.39±0.10(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals
-
Location:
Room A, 23rd Floor, No. 609 Yan'an Road, Gongshu District, Hangzhou, Zhejiang
-
Payment Terms:
TT against copy of documents,D/P,L/C
-
Average lead Time:
5 days
-
Total Annual Revenue:
Above $100 million
-
Year of Establishment:
2020
Company Certificates-
ISO
">Company ProfileLEAPChem is a specialized fine chemical supplier for research, development and production.
LEAPChem provides nearly 200,000 rare and innovative chemical products to support the evolving needs of our customers in research & bulk manufacturing activities.
As a highly customer-oriented enterprise, we are committed to providing high-quality customer services and products to our global customers in a cost-effective and efficient manner.
Our client list includes many major pharmaceutical and science companies, universities, research institutions and chemical catalogue companies.
Methodology: Sound & Stable; Active & Innovative.
Attitude: Conscientious; Ingenious.
Goals: Customer's Satisfaction
We regard client's success as our success.
At LEAPChem, we strive to be the preferred supplier for efficiency increasing and cost lowering in your Research & Production.
To achieve this strategic vision, we always push ourselves to exceed our customer's requirement. By focusing on the aim of 'Beyond Your Expectation', we continually expand our product lines, and enhance our systematic management and human resources.
Welcome to contact us and we look forward to becoming your reliable and preferred partner.
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Silane, (3-chloropropyl)dimethyl-
/ 99.00%
-
-
-
-
2-Acetylthiophene
/ 99.00%
-
-
-
-
3-Pyridylacetic acid hydrochloride
/ 99.00%
-
-
-
-
N-Methylhydroxylamine hydrochloride
/ 99.00%
-
-
-
-
Ornidazole
/ 99.00%
-
-
-
-
N-Demethyl olanzapine
/ 99.00%
-